Butterfly Network’s Handheld Ultrasound Is Reshaping Point-of-Care Diagnostics

Key Takeaways

• Butterfly Network (BFLY) Q1 revenue grew 28% to $24M, beating estimates of $21M.
• The iQ+ handheld ultrasound now has FDA clearance for 22 clinical indications.
• Hospital system and military contracts are the fastest-growing customer segments.
• International expansion particularly to Canada, Australia, and the UK is the key growth driver for H2 2026.

Butterfly Network has achieved something that was considered nearly impossible a decade ago: fitting a complete ultrasound system onto a single semiconductor chip housed in a pocket-sized device. The iQ+ device, which connects to a smartphone app, can perform 22 clinically validated scan types from cardiac to abdominal to musculoskeletal at a fraction of the cost of traditional ultrasound equipment.

The Market Disruption

Traditional ultrasound machines cost $30,000–$150,000 and require dedicated technicians. The Butterfly iQ+ retails for approximately $2,000 and can be operated by trained clinicians without specialized ultrasound certification. In emergency medicine where rapid assessment of cardiac function, fluid status, and pneumothorax can be life-saving the iQ+ has found a compelling product-market fit.